Cynosure Group’s Protagonist Therapeutics PTGX Stock Holding History

Cynosure Group’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,635	Closed	-$489K	–	241
2026 Q1	$489K	Buy	+4,635	New	+$410K	0.06%	85

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Cynosure Group's PTGX Position: Q2 2026 in Review

Cynosure Group sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 4,635 shares — an estimated $489K sold.

Cynosure Group first reported a position in PTGX in Q1 2026 and held it in 1 quarter. The position peaked at $489K in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Cynosure Group reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
Cynosure Group sold 4,635 Protagonist Therapeutics shares in Q2 2026, an estimated $489K.
Cynosure Group first reported a position in Protagonist Therapeutics in Q1 2026 and held it in 1 quarter.
Cynosure Group's Protagonist Therapeutics position peaked at $489K in Q1 2026.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Cynosure Group's 13F filing for Q2 2026, filed 5 Aug 2026.